Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 14;4(7):1512-1517.
doi: 10.1182/bloodadvances.2019000840.

DOACs vs LMWHs in Hospitalized Medical Patients: A Systematic Review and Meta-Analysis That Informed 2018 ASH Guidelines

Affiliations
Free PMC article

DOACs vs LMWHs in Hospitalized Medical Patients: A Systematic Review and Meta-Analysis That Informed 2018 ASH Guidelines

Ignacio Neumann et al. Blood Adv. .
Free PMC article

Abstract

Venous thromboembolism (VTE) is a relatively frequent complication in hospitalized patients, especially in those with risk factors. The benefit of using direct oral anticoagulants (DOACs) for prevention is controversial. This systematic review was performed as part of the American Society of Hematology (ASH) guidelines on VTE, developed in partnership with McMaster University. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Epistemonikos were used as data sources from date of inception to November 2019. We included randomized trials in patients hospitalized for an acute medical disease, evaluating any DOACs vs other pharmacological prophylaxis, and included 3 trials with low risk of bias. We analyzed the effects of DOACs vs low-molecular-weight heparins (LMWHs) at 2 different time points: at the end of the short-term treatment phase (both drugs given for the same period of time) and at the end of the extended prophylaxis period (extended DOACs vs a shorter course of LMWHs). We observed that the use of DOACs did not reduce the risk of pulmonary embolism or symptomatic deep venous thrombosis (DVT) in comparison with LMWHs. However, the risk of major bleeding was slightly increased. Additionally, we observed that the benefit of DOACs previously reported was largely based on the reduction of asymptomatic DVT and was not apparent when only symptomatic events were considered. The use of DOACs in hospitalized medical patients slightly increases the risk of major bleeding with no appreciable benefit over LMWHs.

Conflict of interest statement

Conflict-of-interest disclosure: Full conflict-of-interest declarations for all of the authors of this review are available in Schünemann et al. F.D. and K.B. have received funding from DOAC manufacturers. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
PRISMA flow.
Figure 2.
Figure 2.
Relevant time points for outcome assessments.

Similar articles

See all similar articles
Feedback